Did You Know...
...that after Parker Brothers executives turned down the game of Monopoly because it had "52 fundamental errors" (including taking too long to play), a copy of the game wound up in the home of the company president who stayed up until 1 a.m. to finish playing it? He was so impressed by the game that the next day he wrote to inventor Charles Darrow and offered to buy it!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8110671 | Isolated human chromosome 14 fragment encoding immunoglobulin genes The specification relates to a method for producing a chimeric non-human animal, which comprises preparing a microcell containing a foreign chromosome(s) or a fragment(s) thereof and transferring the foreign chromosome(s) or fragment(s) thereof into a pluripotent ce... | 02/07/2012 |
| 8106177 | Nucleic acids encoding human anti-IL-23 antibodies A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. ... | 01/31/2012 |
| 8097713 | Nucleic acid molecules which encode human anti-CD20 antibodies and methods of use thereof The present invention provides nucleic acid molecules which encode human antibodies or antigen-binding fragments thereof that specifically bind human CD20. Also provided are expression vectors comprising nucleic acid molecules that encode anti-CD20 antibodies, and m... | 01/17/2012 |
| 8088908 | Humanized anti-prostate stem cell antigen monoclonal antibody Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited b... | 01/03/2012 |
| 8080646 | Human monoclonal antibodies to activin receptor-like kinase-1 The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathw... | 12/20/2011 |
| 8067564 | Methods of obtaining a specific binding member that binds eotaxin Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralize eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and ... | 11/29/2011 |
| 8058418 | Polynucleotides encoding heavy and light chains of antibodies to OPGL Compositions comprising polynucleotides encoding heavy and light chains of antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of making such antibodies are described. ... | 11/15/2011 |
| 8053569 | Nucleic acids encoding and methods of producing fusion proteins The invention provides compositions, methods, and kits for increasing transport of agents across the blood brain barrier while allowing their activity once across the barrier to remain substantially intact. The agents are transported across the blood brain barrier v... | 11/08/2011 |
| 8030469 | Anti-CD26 antibodies and methods of use thereof The present invention provides novel anti-CD26 antibodies and other, related polypeptides, as well as novel polynucleotides encoding the antibodies and polypeptides. The invention also provides methods of making the antibodies and polypeptides. Compositions and cell... | 10/04/2011 |
| 8003774 | Identification and engineering of antibodies with variant Fc regions and methods of using same The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc regi... | 08/23/2011 |
| 7994302 | Fully human monoclonal antibodies to IL-13 The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies directed to IL-13. Isolated polynucleotide sequences encoding, and ami... | 08/09/2011 |
| 7982024 | Antibodies to insulin-like growth factor I receptor The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeri... | 07/19/2011 |
| 7960532 | Polynucleotides encoding anticoagulant antibodies This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF with FVII and FX, an inhibit FX activation. The antibodies bind at the s... | 06/14/2011 |
| 7956173 | Nucleic acids coding for humanized antibodies for binding sphingosine-1-phosphate The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragment... | 06/07/2011 |
| 7932372 | Antibodies to MAdCAM The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The invention also relates to human anti-MAdCAM antibodies and ... | 04/26/2011 |
| 7928214 | P-cadherin antibodies The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to P-cadherin, and that function to inhibit P-cadherin. The invention also relates to heavy and light chain immunoglobulins derived from human P-cad... | 04/19/2011 |
| 7919606 | Biological products There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA... | 04/05/2011 |
| 7919607 | Nucleic acids encoding humanized anti-tag 72 CC49 antbodies The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain com... | 04/05/2011 |
| 7915396 | Nucleic acid molecules encoding minimally immunogenic variants of SDR-grafted humanized antibody CC49 Humanized anti-TAG-72 CC49 monoclonal antibodies are disclosed herein. The antibodies include a light chain Complementarity Determining Region (L-CDR)1, a L-CDR2, and a L-CDR3; and a heavy chain Complementarity Determining Region (H-CDR)1, a H-CDR2, and a H-CDR3 fro... | 03/29/2011 |
| 7897743 | Humanized GM-CSF antibodies Chimeric antibodies, as well as fusion proteins which comprise chimeric antibodies, are disclosed. The antibodies bind to GM-CSF, CD-30, and G250 antigen. The fusion proteins include biologically active portions of tumor necrosis factor, or full length tumor necrosi... | 03/01/2011 |
| 7884198 | Polynucleotides encoding humanized and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal... | 02/08/2011 |
| 7879990 | Polynucleotides encoding antibodies that bind to the C35 polypeptide The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladd... | 02/01/2011 |
| 7872113 | Nucleic acids encoding antibodies that bind interleukin-4 receptor The present invention relates to antibodies that bind to the IL-4 receptor, fragments, muteins, and derivatives of such antibodies, nucleic acids encoding such antibodies, fragments, muteins and derivatives, and methods of making and using such antibodies, fragments... | 01/18/2011 |
| 7868152 | Polynucleotides encoding anti-sulfotyrosine antibodies The invention provides anti-sulfotyrosine specific antibodies capable of detecting and isolating polypeptides that are tyrosine-sulfated. The sulfotyrosine antibodies and antibody fragments of the invention may be used to discriminate between the non-sulfated and su... | 01/11/2011 |
| 7847082 | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory sy... | 12/07/2010 |
| 7842797 | Human CDR-grafted antibody and antibody fragment thereof A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereo... | 11/30/2010 |
| 7820807 | Gene constructs coding for CD40-binding activating antibodies Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce ph... | 10/26/2010 |
| 7795413 | Nucleic acids encoding human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and par... | 09/14/2010 |
| 7786284 | Polynucleotides encoding IL-17 receptor A antigen binding proteins The present invention relates to IL-17 receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, and the polynucleotide sequences encoding them, as well as host cells, expression vectors, and methods of making IL-17 receptor A antigen binding prot... | 08/31/2010 |
| 7777019 | Mutated Anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and a... | 08/17/2010 |
| 7777018 | CDR-grafted anti-tissue factor antibodies and methods of use thereof The present invention provides CDR-grated antibodies against human tissue factor that retain the high binding affinity of rodent monoclonal antibodies against tissue factor but have reduced immunogenicity. The present humanized antibodies are potent anticoagulants a... | 08/17/2010 |
| 7777017 | Nucleic acids encoding opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria The present invention encompasses monoclonal antibodies that bind to lipoteichoic acid (LTA) of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro. The invention also provides antibodies h... | 08/17/2010 |
| 7763720 | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequenc... | 07/27/2010 |
| 7763719 | Variants of humanized anti-carcinoma MAb CC49 The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain a... | 07/27/2010 |
| 7754867 | Nucleic acid molecules encoding anti-P-selectin antibodies This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties ca... | 07/13/2010 |
| 7732588 | Tweak receptor The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions me... | 06/08/2010 |
| 7714119 | AAV vector compositions and methods for enhanced expression of immunoglobulins using the same Single AAV vector constructs for expression of an immunoglobulin molecule or fragment thereof and methods of making and using the same are described. The AAV vectors comprise a self-processing cleavage sequence between a first and second immunoglobulin coding sequen... | 05/11/2010 |
| 7714120 | Humanized anti-IL-1 beta antibodies The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind mature human IL-1 Beta. These antibodies, or antigen-binding portions thereof, generally exhibit high binding affinities (low kooff values),... | 05/11/2010 |
| 7667021 | Neutralizing human anti-IGFR antibody The present invention includes isolated nucleic acids encoding fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). Also included are methods of using and producing the antibodies of the invention. ... | 02/23/2010 |
| 7655783 | Methods and compositions for increasing antibody production The invention provides methods and compositions for improved expression and production of recombinant antibodies in host cell expression systems. In particular, prokaryotic expression and production of antibodies with modified hinge cysteine residues are provided. T... | 02/02/2010 |
